View Exam | PowerPak

1. In patients taking oral anticoagulants, the most common source of bleeding in patients presenting to the emergency department is

A. Intracranial B. Epidural C. Gastrointestinal D. Epistaxis

2. Which of the following is a humanized monoclonal antibody for DOAC reversal?

A. Dabigatran B. Andexanet C. Idarucizumab D. Ciraparantag

3. Which of the following is a factor Xa decoy that is structurally similar to factor Xa but enzymatically inactive as an anticoagulant permitting it to bind to an inactivate factor Xa inhibitors?

A. Dabigatran B. Andexanet C. Idarucizumab D. Ciraparantag

4. In patients taking oral anticoagulants, which type of bleeding has the highest risk of death?

A. Intracranial B. Gastrointestinal C. Procedure-related D. Oral

5. If andexanet is not available, which of the following should be administered to a patient to reverse rivaroxaban-associated major bleeding?

A. Vitamin K B. Idarucizumab C. Fresh frozen plasma D. Four-factor prothrombin complex concentrates

6. Which of the following are risk factors for bleeding in patients taking DOACs?

A. Reduced renal function B. Age of more than 80 years C. Concomitant aspirin D. All of the above

7. Which of the following assays can be used to measure the quantity of apixaban in the blood?

A. Prothrombin time B. Activated partial thromboplastin time C. Ecarin clotting time D. Calibrated apixaban anti-Xa assay

8. A 95-kg man with atrial fibrillation taking apixaban 5 mg orally twice daily (dose appropriate for renal function; last dose 4 hours ago) presents to the emergency department with major gastrointestinal bleeding requiring reversal of apixaban. Which of the following is the correct andexanet dose?

A. 400 mg IV bolus followed by 480 mg infused over 120 min B. 400 mg IV bolus followed by 960 mg infused over 120 min C. 800 mg IV bolus followed by 480 mg infused over 120 min D. 800 mg IV bolus followed by 960 mg infused over 120 min

9. In a patient taking dabigatran presenting with motor vehicle trauma requiring major surgery, which of the following is recommended by clinical practice guidelines for continued bleeding despite idarucizumab 5 g administered 2 hours ago?

A. Four-factor prothrombin complex concentrates B. Andexanet C. A second dose of idarucizumab 5 g IV D. Platelet transfusion

10. Ciraparantag:

A. Binds to anticoagulants via noncovalent hydrogen bonds and charge-charge interactions B. Is specific for heparin reversal C. Targets indirect-acting factor Xa inhibitors D. Has not yet been studied in humans

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. In patients taking oral anticoagulants, the most common source of bleeding in patients presenting to the emergency department is

2. Which of the following is a humanized monoclonal antibody for DOAC reversal?

3. Which of the following is a factor Xa decoy that is structurally similar to factor Xa but enzymatically inactive as an anticoagulant permitting it to bind to an inactivate factor Xa inhibitors?

4. In patients taking oral anticoagulants, which type of bleeding has the highest risk of death?

5. If andexanet is not available, which of the following should be administered to a patient to reverse rivaroxaban-associated major bleeding?

6. Which of the following are risk factors for bleeding in patients taking DOACs?

7. Which of the following assays can be used to measure the quantity of apixaban in the blood?

8. A 95-kg man with atrial fibrillation taking apixaban 5 mg orally twice daily (dose appropriate for renal function; last dose 4 hours ago) presents to the emergency department with major gastrointestinal bleeding requiring reversal of apixaban. Which of the following is the correct andexanet dose?

9. In a patient taking dabigatran presenting with motor vehicle trauma requiring major surgery, which of the following is recommended by clinical practice guidelines for continued bleeding despite idarucizumab 5 g administered 2 hours ago?

10. Ciraparantag:

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. In patients taking oral anticoagulants, the most common source of bleeding in patients presenting to the emergency department is

2. Which of the following is a humanized monoclonal antibody for DOAC reversal?

3. Which of the following is a factor Xa decoy that is structurally similar to factor Xa but enzymatically inactive as an anticoagulant permitting it to bind to an inactivate factor Xa inhibitors?

4. In patients taking oral anticoagulants, which type of bleeding has the highest risk of death?

5. If andexanet is not available, which of the following should be administered to a patient to reverse rivaroxaban-associated major bleeding?

6. Which of the following are risk factors for bleeding in patients taking DOACs?

7. Which of the following assays can be used to measure the quantity of apixaban in the blood?

9. In a patient taking dabigatran presenting with motor vehicle trauma requiring major surgery, which of the following is recommended by clinical practice guidelines for continued bleeding despite idarucizumab 5 g administered 2 hours ago?

10. Ciraparantag:

« Return to Activity

Customers who Purchased
this Activity also Purchased